Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMERALD-2
- Sponsors AstraZeneca; AstraZeneca AB
- 11 Apr 2024 Planned End Date changed from 31 Aug 2025 to 31 May 2027.
- 11 Apr 2024 Planned primary completion date changed from 30 Aug 2024 to 29 May 2026.
- 09 Jun 2023 Planned End Date changed from 31 May 2024 to 31 Aug 2025.